IL248671B - A peptide composition containing a mutant of ras peptide and a therapeutic agent - Google Patents

A peptide composition containing a mutant of ras peptide and a therapeutic agent

Info

Publication number
IL248671B
IL248671B IL248671A IL24867116A IL248671B IL 248671 B IL248671 B IL 248671B IL 248671 A IL248671 A IL 248671A IL 24867116 A IL24867116 A IL 24867116A IL 248671 B IL248671 B IL 248671B
Authority
IL
Israel
Prior art keywords
peptide
chemotherapeutic agent
mutant ras
vaccine
peptide vaccine
Prior art date
Application number
IL248671A
Other languages
English (en)
Hebrew (he)
Other versions
IL248671A0 (en
Original Assignee
Targovax Asa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50679896&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL248671(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Targovax Asa filed Critical Targovax Asa
Publication of IL248671A0 publication Critical patent/IL248671A0/en
Publication of IL248671B publication Critical patent/IL248671B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A61K39/001164—GTPases, e.g. Ras or Rho
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
IL248671A 2014-05-06 2016-11-01 A peptide composition containing a mutant of ras peptide and a therapeutic agent IL248671B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14167265 2014-05-06
PCT/EP2015/059861 WO2015169804A1 (en) 2014-05-06 2015-05-05 Peptide vaccine comprising mutant ras peptide and chemotherapeutic agent

Publications (2)

Publication Number Publication Date
IL248671A0 IL248671A0 (en) 2017-01-31
IL248671B true IL248671B (en) 2021-08-31

Family

ID=50679896

Family Applications (1)

Application Number Title Priority Date Filing Date
IL248671A IL248671B (en) 2014-05-06 2016-11-01 A peptide composition containing a mutant of ras peptide and a therapeutic agent

Country Status (16)

Country Link
US (1) US9757439B2 (enExample)
EP (1) EP3140320B1 (enExample)
JP (2) JP2017514847A (enExample)
KR (1) KR20170002563A (enExample)
CN (1) CN106414493A (enExample)
AU (1) AU2015257774B2 (enExample)
BR (1) BR112016025764A2 (enExample)
CA (1) CA2947963A1 (enExample)
CL (1) CL2016002794A1 (enExample)
DK (1) DK3140320T3 (enExample)
ES (1) ES2716923T3 (enExample)
IL (1) IL248671B (enExample)
MX (1) MX2016014414A (enExample)
RU (1) RU2700929C2 (enExample)
SG (2) SG11201608712PA (enExample)
WO (1) WO2015169804A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112016013138A2 (pt) 2013-12-09 2018-01-16 Targovax Asa mistura de peptídeos
CA3042015A1 (en) 2016-10-26 2018-05-03 Modernatx, Inc. Messenger ribonucleic acids for enhancing immune responses and methods of use thereof
MX2019009070A (es) 2017-02-01 2019-10-30 Modernatx Inc Composiciones de arnm terapeuticas inmunomoduladoras que codifican peptidos de mutacion de oncogenes de activacion.
WO2018145020A1 (en) * 2017-02-03 2018-08-09 The Medical College Of Wisconsin, Inc. Kras peptide vaccine compositions and method of use
SG11202012653XA (en) 2018-06-19 2021-01-28 Biontech Us Inc Neoantigens and uses thereof
WO2020002650A1 (en) 2018-06-29 2020-01-02 Targovax Asa A formulation
CN109550044B (zh) * 2018-10-19 2022-05-03 杭州纽安津生物科技有限公司 通用性多肽疫苗及其在制备治疗/预防胰腺癌药物中的应用
EP3982980A4 (en) * 2019-06-12 2023-11-29 BioNTech US Inc. NEOANTIGEN COMPOSITIONS AND USES THEREOF
CN113416241B (zh) * 2020-04-09 2022-04-08 北京臻知医学科技有限责任公司 一种用于诱导肿瘤特异性免疫响应的通用型抗原肽库及试剂盒
WO2022026621A1 (en) * 2020-07-29 2022-02-03 Sqz Biotechnologies Company Methods to stimulate immune responses to mutant ras using anucleate cells
KR20230058389A (ko) * 2020-07-29 2023-05-03 에스큐지 바이오테크놀로지스 컴퍼니 유핵 세포를 사용해 돌연변이체 ras에 대한 면역 반응을 자극하는 방법
JP2023550515A (ja) * 2020-11-24 2023-12-01 シャンハイ、ケンパーソー、バイオテクノロジー、カンパニー、リミテッド Ｒａｓ突然変異体エピトープペプチドおよびｒａｓ突然変異体を認識するｔ細胞受容体
EP4423256A2 (en) * 2021-10-28 2024-09-04 Genentech, Inc. Systems and methods to identify mhc-associated antigens for therapeutic intervention
EP4522192A2 (en) * 2022-05-12 2025-03-19 The Johns Hopkins University Neoantigen vaccines for cancer prevention
CN122341725A (zh) * 2023-11-15 2026-07-03 长江生命科技发展有限公司 用于预防或治疗kras相关疾病或病症的药物组合物和方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9103974D0 (en) 1991-02-26 1991-04-10 Norsk Hydro As Therapeutically useful peptides or peptide fragments
GB2328689A (en) 1997-08-27 1999-03-03 Norsk Hydro As Peptides based on the p21 ras proto-oncogene protein for the treatment of cancer
NO309798B1 (no) 1999-04-30 2001-04-02 Targovax As Peptidblanding, samt farmasoytisk sammensetning og kreftvaksine som innbefatter peptidblandingen
JP4914990B2 (ja) 2002-12-16 2012-04-11 グローブイミューン，インコーポレイテッド 動物を癌から守るための治療用組成物
US20140199405A1 (en) 2013-01-11 2014-07-17 Abraxis Bioscience, Llc Method for treating cancer based on mutation status of k-ras
BR112016013138A2 (pt) 2013-12-09 2018-01-16 Targovax Asa mistura de peptídeos

Also Published As

Publication number Publication date
JP2020100650A (ja) 2020-07-02
EP3140320B1 (en) 2018-12-26
JP7304629B2 (ja) 2023-07-07
EP3140320A1 (en) 2017-03-15
US20170065694A1 (en) 2017-03-09
KR20170002563A (ko) 2017-01-06
RU2016147527A (ru) 2018-06-08
US9757439B2 (en) 2017-09-12
CN106414493A (zh) 2017-02-15
DK3140320T3 (en) 2019-04-15
BR112016025764A2 (pt) 2018-01-16
RU2016147527A3 (enExample) 2019-01-21
MX2016014414A (es) 2017-02-23
CA2947963A1 (en) 2015-11-12
RU2700929C2 (ru) 2019-09-24
ES2716923T3 (es) 2019-06-18
AU2015257774A1 (en) 2016-12-22
IL248671A0 (en) 2017-01-31
CL2016002794A1 (es) 2017-06-09
WO2015169804A1 (en) 2015-11-12
SG10201809701TA (en) 2018-12-28
AU2015257774B2 (en) 2018-12-20
JP2017514847A (ja) 2017-06-08
SG11201608712PA (en) 2016-11-29

Similar Documents

Publication Publication Date Title
IL248671A0 (en) A peptide composition containing a mutant of ras peptide and a therapeutic agent
IL249186A0 (en) Anti-cd20 glycoantibodies and their uses
SG10202002593SA (en) Activated bifidobacteria and methods of use thereof
IL247014A0 (en) 6-heteroaryloxy and 6-aryloxy-quinoline-2-carboxamides and their use
SI3303396T1 (sl) Protitelesa proti OX40 in njihova uporaba
PL3152226T3 (pl) Modyfikowane cyklopentapeptydy i ich zastosowania
IL248424B (en) Neuroprotective substances and their uses
IL287985A (en) A peptide derived from koc1 and a component containing it
ZA201805977B (en) Mycobacteriophages capable of delivering auto-luminescent elements and uses thereof
IL257335A (en) A depdc1-derived peptide and a component containing it
PT3519025T (pt) Dispositivo de administração
IL250235A0 (en) A peptide derived from urlc10 and a component containing it
IL251289A0 (en) New peptide derivatives and their use
SG10201501373WA (en) Contrast Agent And Applications Thereof
IL250215A0 (en) A peptide derived from cdca1 and a component containing it
HUE062120T2 (hu) Peptid-származék és alkalmazása
PL3307080T3 (pl) Środek słodzący oraz jego zastosowanie
SG11201610918RA (en) Peptides and uses thereof
GB201401673D0 (en) Esculentin-2CHa peptide and analogues thereof
IL247448A0 (en) Peptides and methods of use
PL3094338T3 (pl) Oznaczenie i lek
GB2545167B (en) Cloches and use thereof
PL3229772T3 (pl) 6-arylo-9-glikozylopuryny i ich zastosowanie